Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0
|
作者：
Ducreux, M. P. [1 ]
Cheng, A-L. [2 ]
Qin, S. [3 ]
Zhu, A. X. [4 ]
Ikeda, M. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Galle, P. R. [10 ]
机构：
[1] Gustave Roussy, Med Oncol, Villejuif, France
[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan
[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea
[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782TiP
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [11] Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
    Qin, Shukui
    Ren, Zhenggang
    Feng, Yin-Hsun
    Yau, Thomas
    Wang, Baocheng
    Zhao, Haitao
    Bai, Yuxian
    Gu, Shanzhi
    Li, Lindong
    Hernandez, Sairy
    Xu, Derek-Zhen
    Mulla, Sohail
    Wang, Yifan
    Shao, Hui
    Cheng, Ann Lii
    LIVER CANCER, 2021, 10 (04) : 296 - 308
  • [12] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
    Kudo, Masatoshi
    Finn, Richard S. S.
    Galle, Peter R. R.
    Zhu, Andrew X. X.
    Ducreux, Michel
    Cheng, Ann-Lii
    Ikeda, Masafumi
    Tsuchiya, Kaoru
    Aoki, Ken-ichi
    Jia, Jing
    Lencioni, Riccardo
    LIVER CANCER, 2023, 12 (03) : 238 - 250
  • [13] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDY
    Zhu, Andrew X.
    Finn, Richard
    Ducreux, Michel
    Hu, Youyou
    Sommer, Nicolas
    Verret, Wendy
    Kulik, Laura M.
    Galle, Peter R.
    HEPATOLOGY, 2021, 74 : 646A - 647A
  • [14] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
    Lu, Linbin
    Zheng, Peichan
    Pan, Yan
    Huang, Shanshan
    Shao, Erqian
    Huang, Yan
    Wang, Xuewen
    Chen, Yayin
    Cuo, Gongbao
    Yang, Hongyi
    Guo, Wangting
    Shi, Yanhong
    Wu, Zhixian
    Chen, Xiong
    BRITISH JOURNAL OF CANCER, 2023, 129 (04) : 620 - 625
  • [15] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [16] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
    Linbin Lu
    Peichan Zheng
    Yan Pan
    Shanshan Huang
    Erqian Shao
    Yan Huang
    Xuewen Wang
    Yayin Chen
    Gongbao Cuo
    Hongyi Yang
    Wangting Guo
    Yanhong Shi
    Zhixian Wu
    Xiong Chen
    British Journal of Cancer, 2023, 129 : 620 - 625
  • [17] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
    Li, Daneng
    Toh, Han Chong
    Merle, Philippe
    Tsuchiya, Kaoru
    Hernandez, Sairy
    Verret, Wendy
    Nicholas, Alan
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (06) : 558 - 571
  • [18] Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
    Espinoza, Magdalena
    Muquith, Maishara
    Lim, Mir
    Zhu, Hao
    Singal, Amit G.
    Hsiehchen, David
    GASTROENTEROLOGY, 2023, 165 (01) : 286 - +
  • [20] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Salem, Riad
    Galle, Peter
    Finn, Richard
    Ducreux, Michel
    Singal, Amit
    Nicholas, Alan
    Hernandez, Sairy
    Verret, Wendy
    Merle, Philippe
    Zhu, Andrew
    JOURNAL OF HEPATOLOGY, 2021, 75 : S246 - S247
12345